Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Hasselt University · Jessa Hospital · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
655
total citations
- FWCI
- 69.66
- Percentile
- 100%
- References
- 31
Citations per year
Authors
16- PVPascal VranckxCorresponding
Hasselt University, Jessa Hospital
- MVMarco Valgimigli
University Hospital of Bern, University of Bern
- LELars Eckardt
Atrial Fibrillation NETwork, University of Münster
- JGJan G.P. Tijssen
Amsterdam University Medical Centers, Cardialysis (Netherlands), University of Amsterdam
- TLThorsten Lewalter
University of Bonn, Atrial Fibrillation NETwork, München Klinik
Topics & keywords
Topics
Keywords
- Medicine
- Edoxaban
- Conventional PCI
- Atrial fibrillation
- Percutaneous coronary intervention
- Internal medicine
- Vitamin K antagonist
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.